Crowdonomics
WatchlistPortfolio
All companies

Jabez Biosciences, Inc.

Operating

Biotech · Zionsville, IN

Estimated pre-money ⓘ
$30.7M
As of Nov 2024 · from Rule 506(b) Private Offering (2024) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$3,096,210
Crowd $38K · Private $3.1M · 7 rounds since 2024
Latest share price
$1.00
Rule 506(b) · Common Stock · Nov 2024 offering price · down round

Financials

FY2023–FY2025 · from SEC filings · hover any figure for its source
$0
−$13K
2023
$0
−$1.1M
2024
$0
−$4.7M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2023 audited
FY2024 audited
FY2025 audited
Income statement
Revenue
$0
$0
$0
Cost of goods sold
$0
$0
—
Net income
-$12,613
-$1,128,990
-$4,653,021
Balance sheet
Cash
$12,000
$324,007
$23,433
Accounts receivable
$0
—
—
Total assets
$12,000
$1,066,296
$611,578
Long-term debt
$22,500
—
—
Total liabilities
$22,613
$1,415,315
$1,381,707
Other
Headcount
1
—
—

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$61.4M
est. pre-money
$30.7M
est. pre-money
Reg A+ · Equity · Sep 2024
Rule 506(b) · Common · Nov 2024

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Share price over rounds

log scale
$2.00$0.6866$0.2357
Aug 2024Nov 2024
Round offering price or verified disclosed saleDisclosed sale, unverified or year-onlyDown round · Nov 2024 (-50%)

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Cap table

Share counts as of Apr 27, 2026
ClassOutstandingVotes / shareShare of totalLast price
Common Stock41,361,968—100.0%$0.2357Aug 2024

Shares outstanding over timein today's share terms

73M36M0
Sep 2024Apr 2026
Class A common stockCommon StockRound opened

Changes in named holdersshares in today's terms · % of all shares at the time

Principal holders% as the filing states it, Apr 30, 2026

  • Tamara Jovonovich6,200,000 Common Stock15.0%of company
  • Robert Lewis6,000,000 Common Stock14.5%of company
  • Eagle Investment Group, LLC4,667,000 Common Stock11.3%of company
  • Marlew, LTD4,467,000 Common Stock10.8%of company
  • MedTek, LLC2,365,000 Common Stock5.72%of company
  • Brian Cogley447,200 Common Stock1.08%of company
  • GoLabs Research and Development, LLC28,301 Common Stock0.07%of company
  • Everyone else (not named in filings)41.5%

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Rule 506(b) · Common Stock · Nov 2024Open
Raised $250.5KInvestors 3Est. pre-money $30.7M
Rule 506(b) · Common Stock · Aug 2024Open
Raised $1.3MInvestors 18
Rule 506(b) · Equity · Jun 2024Open
Raised $31.2KInvestors 8
Reg A+ · Equity · Sep 2024Closed
Raised $38K / $10MEst. pre-money $61.4M
Private · Convertible Note · Mar 2026Closed
Raised $500K
Rule 506(b) · Convertible Note · Apr 2025Closed
Raised $200K

Team

5 people
Brian Cogley
Chief Financial Officer and Director
Robert Lewis
Chief Operating Officer and Director
Tamara Jovonovich
President and Director
Bruce Cassidy
Independent Director
Martin Lewis
Director

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

SEC filings

View all 14 filings on EDGAR
  • Form 1-ZJun 12, 20260001213900-26-068313
    EDGAR
  • Form 1-KApr 30, 20260001213900-26-050100
    EDGAR
  • Form DMar 26, 20260001213900-26-034473
    EDGAR
  • Form D/AOct 28, 20250001213900-25-103046
    EDGAR
  • Form DOct 21, 20250001213900-25-100637
    EDGAR
  • Form DOct 21, 20250001213900-25-100745
    EDGAR
  • Form 1-SASep 30, 20250001213900-25-093470
    EDGAR
  • Form 1-KMay 6, 20250001213900-25-039855
    EDGAR
Source: SEC EDGARCIK 0002038185FLShare price $1.00Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.